Related Experiment Video

Updated: May 30, 2026

Transient Middle Cerebral Artery Occlusion Model of Neonatal Stroke in P10 Rats
07:56

Transient Middle Cerebral Artery Occlusion Model of Neonatal Stroke in P10 Rats

Published on: April 21, 2017

Old and new antithrombotic drugs in neonates and infants

Guy Young1

  • 1Hemostasis and Thrombosis Center, Children's Hospital Los Angeles, Los Angeles, CA, USA. gyoung@chla.usc.edu

Seminars in Fetal & Neonatal Medicine
|August 6, 2011
PubMed

Insights

Pediatric thrombosis is rising, prompting research into safer anticoagulants beyond traditional options. Newer agents like bivalirudin and argatroban show promise, with ongoing trials for oral anticoagulants to improve pediatric care.

Area of Science:

  • Pediatric Hematology
  • Pharmacology
  • Thrombosis Research

Background:

  • Increasing incidence of thromboembolic complications in children.
  • Limitations of current anticoagulants (heparin, LMWH, warfarin) in pediatric populations.
  • Growing need for safer and more effective anticoagulation therapies for children.

Purpose of the Study:

  • To review current and emerging anticoagulant agents for pediatric use.
  • To provide recommendations for the clinical application of newer agents.
  • To highlight ongoing research and future directions in pediatric anticoagulation.

Main Methods:

  • Review of clinical trials and studies on anticoagulants in children.
  • Evaluation of pharmacologic properties of newer agents (bivalirudin, argatroban, fondaparinux).
  • Analysis of ongoing research for novel oral anticoagulants and their regulatory pathways.

Main Results:

  • Established recommendations for the use of bivalirudin, argatroban, and fondaparinux in pediatric patients.
  • Identification of areas requiring further research to expand the indications for these agents.
  • Anticipation of significant advancements in pediatric anticoagulation management within the next decade.

Conclusions:

  • Current evidence supports the use of specific newer anticoagulants in children.
  • Further studies are essential to broaden the application of these agents.
  • Pediatric thrombosis research is advancing, promising improved treatment strategies.

More Related Videos

A Neonatal Rodent Model of Retroorbital Vein Injection04:39

A Neonatal Rodent Model of Retroorbital Vein Injection

Published on: February 23, 2024

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...